Calocurb has reported the publication of a randomized, double-blind clinical study showing that its Amarasate bitter hop extract was associated with greater reductions in body weight, fat mass and estimated visceral fat than placebo after 24 weeks. Participants receiving the active intervention lost an average of 3.8 kilograms, equivalent to 4.3% of their baseline body weight, while bioelectrical impedance measurements showed no reduction in estimated skeletal muscle mass.
The study, published online in Obesity Pillars on July 17, 2026, offers more substantial evidence than the short-duration appetite and fasting studies previously associated with Amarasate. It does not, however, establish Calocurb as equivalent to prescription glucagon-like peptide-1 receptor agonists, prove that muscle function was preserved or demonstrate that the observed weight reduction will be maintained after treatment stops.
Calocurb is marketed as a dietary supplement rather than an approved obesity medicine. Its commercial positioning relies on the claim that gastrointestinal delivery of a concentrated bitter hop extract stimulates the body’s own appetite-related hormones, including glucagon-like peptide-1, cholecystokinin and peptide YY. That description is mechanistically and regulatorily different from prescription medicines that directly activate glucagon-like peptide-1 receptors for prolonged periods.
What does the 24-week Calocurb trial actually show about weight and body composition?
The parallel-group study enrolled 150 adult men and women with overweight or obesity. Participants were assigned to receive either placebo or 500 milligrams of bitter hop extract daily, divided into doses taken at least one hour before their two largest meals. Both groups participated in a 24-week weight-management programme that included monthly group seminars offering lifestyle advice. Body weight, subjective appetite measures and body composition estimated through bioelectrical impedance analysis were assessed every four weeks.
A total of 128 participants completed the programme, including 65 in the active-treatment group and 63 in the placebo group. The Calocurb group recorded an average reduction of 3.8 kilograms from baseline, compared with 0.4 kilograms in the placebo group. Expressed as a percentage, mean body weight declined by 4.3% with the bitter hop extract and 0.5% with placebo.
The body-composition findings were more differentiated than the change in scale weight alone. Estimated fat mass declined by 4.5 kilograms in the active group and 0.7 kilograms in the placebo group. Estimated visceral fat area fell by 32.5 square centimetres with Calocurb, compared with 9.1 square centimetres under placebo. The published abstract reported that the between-group differences in body weight, fat mass and estimated visceral fat were statistically significant.
Estimated skeletal muscle mass increased by 0.9 kilograms in the active group and 0.2 kilograms in the placebo group. Crucially, the difference in muscle-mass change between the groups was not statistically significant. The most defensible interpretation is therefore that the study found no measured loss of skeletal muscle in either group, rather than proving that Calocurb independently builds or uniquely protects muscle.
That distinction matters because the commercial headline of preserving muscle is directionally supported by the measurements, while a stronger claim that the product caused muscle gain would exceed the reported statistical evidence.
Why does the muscle-preservation claim require more caution than the headline suggests?
Body composition was measured using bioelectrical impedance analysis, which estimates fat, lean tissue and body water from the resistance of electrical currents passing through the body. It is accessible and practical for repeated study visits, but readings can be influenced by hydration, meal timing, physical activity and the equations used by a particular device.
The trial therefore provides evidence that skeletal muscle mass did not decline according to the bioelectrical impedance method used. It does not provide the same degree of compositional precision that could come from dual-energy X-ray absorptiometry or magnetic resonance imaging. Nor does the available publication summary indicate that participants underwent strength testing, walking assessments, exercise-capacity measurement or other evaluations of muscle function.
Muscle quantity and muscle function are related but not interchangeable. An intervention may appear to preserve estimated lean mass without demonstrating that strength, mobility or metabolic function has improved. Conversely, reductions in measured lean mass during weight loss do not necessarily represent an equivalent loss of contractile skeletal muscle.
Recent systematic reviews examining prescription glucagon-like peptide-1 receptor agonists have also shown that the lean-mass debate is more nuanced than promotional comparisons sometimes suggest. Absolute lean mass can decline during pharmacological weight loss, but body composition may still improve because fat mass falls more substantially. Researchers have consequently emphasised nutritional support, adequate protein intake, physical activity and functional assessment rather than treating every reduction in lean mass as evidence of harmful muscle deterioration.
Calocurb’s finding is therefore commercially interesting, particularly as consumers increasingly ask whether weight-loss interventions disproportionately reduce lean tissue. It remains an early body-composition signal that requires confirmation with more precise imaging and functional endpoints.
How does Amarasate differ from prescription GLP-1 receptor agonists despite similar language?
Amarasate is a concentrated extract derived from bitter hop flowers. The delayed-release capsule is intended to deliver the extract to the intestine, where bitter taste receptors are proposed to stimulate endogenous secretion of appetite-related hormones.
Earlier randomized studies provide biological support for that mechanism. In a crossover trial involving 19 healthy-weight men, gastric and duodenal administration of bitter hop extract altered glucagon-like peptide-1, cholecystokinin and peptide YY responses and reduced short-term energy intake compared with placebo. A separate study involving women undergoing a 24-hour fast found reductions in subjective hunger, food cravings and energy intake at the subsequent meal.
Those studies were small and focused principally on acute hormone, appetite or food-intake responses. The new 24-week trial represents an important progression because it asks whether those short-term effects can translate into sustained changes in weight and body composition.
The evidence does not make Amarasate a natural version of semaglutide, tirzepatide or liraglutide. Prescription glucagon-like peptide-1 medicines are receptor agonists designed to produce pharmacological activity over extended periods. They have been studied across large, multi-centre development programmes assessing weight loss, glycaemic control, cardiovascular outcomes, adverse events and longer-term treatment.
Calocurb stimulates endogenous hormone release through an intestinal bitter-receptor pathway, according to its proposed mechanism. Calling both approaches “GLP-1” may be useful for consumer recognition, but it can blur major differences in molecular action, treatment intensity, evidence maturity and regulatory oversight.
No head-to-head study has compared Calocurb with a prescription obesity medicine. Comparisons using percentages from unrelated studies would be unreliable because the populations, treatment durations, lifestyle programmes, baseline risks, adherence requirements and statistical methods differ.
Does a 4.3% mean weight reduction create a credible commercial position for Calocurb?
A mean reduction of 4.3% over 24 weeks is modest relative to the weight loss reported in late-stage studies of leading prescription obesity medicines. It is nevertheless considerably greater than the 0.5% reduction observed in the study’s placebo group, making the result more commercially meaningful than a simple before-and-after consumer study.
The product’s most plausible market position is not as a replacement for prescription treatment among people who meet medical criteria for pharmacotherapy. Current clinical guidance supports evidence-based obesity medicines alongside lifestyle modification for appropriate adults, with semaglutide and tirzepatide among the treatments backed by substantially larger clinical datasets.
Calocurb may instead seek demand from consumers looking for a prescription-free weight-management adjunct, people who are ineligible or unwilling to use injectable medicines, or individuals seeking appetite support alongside dietary and exercise changes. The company also promotes the product for weight maintenance after discontinuation of prescription glucagon-like peptide-1 therapy, although the new study did not specifically evaluate people transitioning from those medicines.
That last distinction is commercially important. Weight maintenance after stopping pharmacological obesity treatment is a specific clinical challenge. Evidence from a general overweight and obesity population cannot automatically establish efficacy in patients who have discontinued semaglutide, tirzepatide or another prescription therapy.
Calocurb lists a United States price of $89.99 for a one-month supply. The product is sold as a dietary supplement, and its website states that its claims have not been evaluated by the United States Food and Drug Administration, New Zealand’s Medsafe or the European Medicines Agency unless expressly specified. It is not approved to diagnose, treat, cure or prevent obesity or another disease.
For the company, publication in a peer-reviewed obesity journal provides a more credible foundation for practitioner engagement and consumer marketing. Commercial conversion will still depend on whether customers consider a mean 3.8-kilogram reduction over six months meaningful enough to justify the cost and twice-daily pre-meal routine.
What safety and tolerability evidence will clinicians and consumers still need to examine?
Calocurb’s marketing highlights the absence of ongoing side effects, but absolute safety language would not be supported by the available evidence. Earlier trials of the same bitter hop extract reported gastrointestinal effects, including loose stools, nausea, bloating, abdominal discomfort and heartburn, although delayed intestinal delivery appeared more tolerable than gastric delivery in one study.
In the new 24-week trial, one participant in each study group reportedly withdrew because of capsule-related side effects. Five participants receiving the active extract reduced their dose to half of the planned amount and one reduced it to one quarter because of tolerability, compared with one dose reduction in the placebo group. Most participants were nevertheless reported to have reached the full dose following titration.
These disclosures do not suggest a major identified safety problem, but they show why “natural” should not be interpreted as synonymous with side-effect free. A full assessment would require the complete adverse-event table, severity classifications, timing, treatment relationship, discontinuation data and information about any laboratory or metabolic monitoring performed.
The evidence is also weighted toward relatively young adults. The study population had a mean age of approximately 35 years, and around three quarters of participants were women. The findings may not fully represent older adults, people with sarcopenia, complex metabolic disease, gastrointestinal disorders or multiple medications.
What would move Calocurb from an encouraging supplement study to a durable evidence platform?
The trial gives Calocurb a credible efficacy signal. Randomisation, blinding, placebo control, six months of treatment and peer-reviewed publication materially strengthen the company’s evidence position. The separation between the active and placebo groups also suggests that the observed result was not explained solely by the lifestyle seminars provided to both arms.
A more durable clinical case would require replication by independent researchers, larger and more diverse populations, clearer adverse-event reporting and body-composition testing using dual-energy X-ray absorptiometry or magnetic resonance imaging. Strength, physical performance and quality-of-life endpoints would be particularly valuable if muscle preservation remains central to the product’s positioning.
Longer follow-up would also need to show whether weight and fat reductions persist, plateau or reverse after treatment ends. Although the company’s announcement referred to follow-up of participants, the headline publication data focus on the 24-week treatment period, leaving post-treatment durability as an important question.
The immediate significance of the study is therefore not that Calocurb has matched prescription glucagon-like peptide-1 therapies. It is that a marketed bitter hop supplement has produced a statistically supported weight and fat reduction in a randomized six-month study while showing no loss of skeletal muscle under the measurement method used.
Calocurb now has evidence that can support a more serious discussion with weight-management practitioners. Its next test is whether that result can be reproduced with stronger body-composition methods, broader patient populations and sufficiently detailed safety data to separate a promising nutraceutical signal from the far larger number of supplement claims that never progress beyond marketing.